Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients when standard therapy fails

NCT ID NCT07315113

Recruiting now Disease control Sponsor: Nuvectis Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated Jun 04, 2026 · Updated 25 times

Summary

This early-stage study tests a new drug called NXP900 combined with the standard drug osimertinib in 18 adults with advanced EGFR-mutant lung cancer that has gotten worse on osimertinib alone. The goal is to see if the combination is safe and can shrink tumors or slow the cancer's growth. This is not a cure, but aims to give patients more control over their disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR MUTATION POSITIVE NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Massachusetts General Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • NEXT Houston

    RECRUITING

    Houston, Texas, 77054, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.

EGFR MUTATED NON-SMALL CELL LUNG CANCER PATIENTS EGFR MUTATION POSITIVE NON-SMALL CELL LUNG CANCER